Aquestive Therapeutics (NASDAQ:AQST) Insider Lori Braender Sells 40,102 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Lori Braender sold 40,102 shares of Aquestive Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $167,225.34. Following the completion of the sale, the insider directly owned 442,879 shares in the company, valued at $1,846,805.43. This trade represents a 8.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Aquestive Therapeutics Stock Up 2.5%

Aquestive Therapeutics stock traded up $0.11 during trading on Wednesday, hitting $4.31. The stock had a trading volume of 1,170,828 shares, compared to its average volume of 5,614,740. The stock’s 50 day moving average is $4.13 and its two-hundred day moving average is $5.22. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $7.55. The stock has a market cap of $525.38 million, a price-to-earnings ratio of -5.52 and a beta of 1.61.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The business had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million. As a group, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Aquestive Therapeutics News Summary

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Analyst note/valuation — A Seeking Alpha write‑up reiterates a Buy on AQST and argues Anaphylm is closer to FDA approval after addressing CRL packaging/labeling issues; the author models an $8 fair value (≈87% upside), high adoption probabilities and eventual profitability by 2029 while warning additional financing may be needed by end‑2027. Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
• Positive Sentiment: Broker upgrades/estimate revisions — HC Wainwright raised several near‑term EPS estimates (Q1–Q4 2026 and select 2027 quarters) and lifted its FY2026 view (from roughly -$0.61 to -$0.51), signaling modestly improved operating outlook assumptions. This reduces downside to short‑term guidance risk but the company remains loss‑making. AQST Stock Page
• Neutral Sentiment: Industry coverage — The Globe and Mail included Aquestive in a list of healthcare stocks analysts are bullish on, providing supportive media attention but no company‑specific catalytic news. Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
• Neutral Sentiment: Corporate governance — Aquestive granted an inducement equity award to its Chief Medical Officer under Nasdaq rules; standard retention/compensation action (minor dilution/expense implications). Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Legal risk — Multiple law firms (Rosen, Johnson Fistel, Bernstein Liebhard, Faruqi & Faruqi, Gross Law) have announced or are soliciting plaintiffs for securities class actions covering purchases from June 16, 2025 to Jan 8, 2026; litigation could increase legal costs, management distraction and limit upside until resolved. Note deadlines for lead plaintiff motions are being publicized (e.g., May 4, 2026). AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
• Negative Sentiment: Market data anomaly — Short‑interest reports show a reported surge but contain inconsistent/erroneous values (zeros/NaN). If real, rising short interest would add selling pressure; current published figures appear unreliable and should be confirmed via exchange filings. (No external link provided.)

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Finally, Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and an average price target of $8.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Aquestive Therapeutics by 30.8% during the third quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock valued at $31,651,000 after buying an additional 1,333,627 shares during the period. Federated Hermes Inc. boosted its position in shares of Aquestive Therapeutics by 159.4% in the fourth quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock valued at $13,132,000 after acquiring an additional 1,249,044 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Aquestive Therapeutics by 6,233.4% in the fourth quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock valued at $7,569,000 after acquiring an additional 1,153,175 shares during the period. Commonwealth Equity Services LLC purchased a new position in Aquestive Therapeutics during the third quarter valued at approximately $5,918,000. Finally, Wells Fargo & Company MN increased its holdings in Aquestive Therapeutics by 804.6% during the 4th quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock worth $7,678,000 after acquiring an additional 1,057,145 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.